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H epatitis-associated aplastic anemia (HAAA) is a rare cause of acquired aplastic anemia (AA),  
which develops within approx.  7 months of the onset of 
hepatitis [1].  A study conducted in Japan estimated that 
HAAA accounted for approx.  12% of pediatric cases of 
acquired AA [2].  Most of those cases were seronegative 
for hepatitis viruses including hepatitis A,  hepatitis B,  
hepatitis C,  Epstein-Barr virus,  and cytomegalovirus.
HAAA is a devastating disease without treatment,  
but it is curable with immunosuppressive therapy (IST) 
or hematopoietic stem cell transplantation (HSCT).  The 
pathophysiology of HAAA is not fully understood.  
Abnormal cytokine release and the expansion of cyto-
toxic T cells is suspected to trigger simultaneous fulmi-
nant hepatitis and bone marrow dysfunction [3].  In 
most cases of HAAA,  hematopoiesis recovers soon after 
the initiation of IST: we were able to find only two case 
reports of HAAA recurring > 10 years after a first epi-
sode of HAAA treated with IST.  In those 2 cases,  an 
abnormal immune reaction against both hematopoietic 
stem cells and hepatocytes is suspected to have been 
sustained,  even after successful IST [4 , 5].
Here we describe the development of HAAA in a 
male following a living-donor liver transplantation 
(LDLT) for idiopathic fulminant hepatitis.  The patient’s 
hematopoiesis recovered following IST with glucocorti-
coid and horse anti-thymoglobulin (ATG).  The patient 
had been well,  using tacrolimus prophylactic therapy 
against hepatic allograft rejection,  but a bone marrow 
examination performed 10 years after the LDLT 
revealed hypocellular marrow with neither dysplastic 
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change nor abnormal karyotype.  We suspect that an 
abnormal immune reaction persisted in this patient,  
and that the tacrolimus treatment may have been effec-
tive in preventing recurrent impaired hematopoiesis as 
well as hepatic allograft rejection.
Case Report
A 16-month-old Japanese male presented with jaun-
dice,  clay-colored stool,  and hepatomegaly.  He under-
went surgery to repair an inguinal hernia at 2 months of 
age and an umbilical hernia at 5 months.  He did not 
have any other remarkable medical history through the 
prenatal and neonatal period.  He did not have any fam-
ily history of hepatitis or autoimmune diseases.  Blood 
testing revealed abnormal liver function,  elevated bili-
rubin,  decreased platelet count,  and coagulopathy,  
suggesting the development of acute liver failure.
The patient was transferred to our hospital as a 
potential liver transplant candidate.  He presented with 
lethargy,  jaundice,  and petechiae.  His liver was palpa-
ble at the right midclavicular line,  5 cm below the cos-
tal margin.  His spleen was not palpable.  Laboratory 
tests indicated fulminant hepatitis and acute liver fail-
ure,  with aspartate transaminase (AST) 4,240 IU/L,  
alanine transaminase (ALT) 3,170 IU/L,  albumin 
3.77 g/dL,  platelet count 35,000/μL,  ammonia 85 μg/dL,  
prothrombin time (PT) 39.8 sec (20%),  and activated 
partial thromboplastin time (aPTT) 139.4 sec.  At this 
time point,  pancytopenia was not seen,  with a normal 
white blood cell count (WBC) 7,800/µL and slightly 
decreased hemoglobin at 11.7 g/dL.  The anti-nuclear 
antibody index was 27.3.  Other autoimmune antibodies 
were not examined.  The IgG,  IgA and IgM levels were 
1,318 mg/dL,  159 mg/dL and 180 mg/dL,  respectively.  
Serology for hepatitis A,  hepatitis B,  hepatitis C,  her-
pes simplex virus,  Epstein-Barr virus,  and cytomega-
lovirus was negative.  Serology for Parvovirus B19 was 
not examined.
The patient was diagnosed as having fulminant idio-
pathic hepatic failure.  He received 2 courses of 
exchange transfusion,  but his liver function did not 
fully improve,  and his level of consciousness gradually 
deteriorated.  An ABO-compatible LDLT from his 
mother was performed.  After the LDLT,  prophylaxis 
against liver allograft rejection with prednisolone and 
tacrolimus was initiated.  The patient’s liver failure 
improved following the LDLT,  but his platelet count 
remained below 100,000/μL.  Moreover,  severe anemia 
and leukocytopenia developed.
A bone marrow examination performed 18 days 
after the LDLT showed severe hypocellular marrow with 
a decreased nucleated cell count (NCC) and megakary-
ocytes (Table 1).  A karyotype analysis with the 
G-banding method revealed 46,  XY.  The diagnosis of 
HAAA was made.
Frequent transfusion therapy was required,  and no 
HLA-matched donor for allogenic hematopoietic stem 
cell transplantation could be found.  Therefore,  IST was 
performed with horse ATG at a single dose of 8 mg/kg 
on the first day and 17 mg/kg for the following 4 days 
with reference to the drug label.  Methyl-prednisolone 
(mPSL) at a dose of 2 mg/kg/day was administerd for 
7 days along with ATG.  Then mPSL was switched to 
prednisolone,  which was tapered over a year and finally 
discontinued.  Granulocyte-colony stimulating factor 
(G-CSF) at a dose of 144 µg/m2 was initiated 13 days 
prior to IST and its dose was increased to 400 µg/m2 on 
the 9th day of administration.  The patient’s pancytope-
nia improved gradually.  Because neutrophil count 
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Table 1　 Analysis of bone marrow aspirates and peripheral blood over time since liver transplant
Time since liver transplant
18 days 78 days 6 months 10 years
Bone marrow aspirate
Nucleated cell count (/μL) 12,000 120,000 264,000 87,000
Megakaryocyte count (/μL) 7 35 N/A N/A
Erythroblast count (/μL) 360 29,000 33,800 14,500
Peripheral blood
Absolute neutrophil count (/μL) 540 1,700 4,900 2,200
Platelet count (/μL) 22,000 124,000 121,000 128,000
Hemoglobin (g/dL) 7.5 11.9 14.0 13.5
increased over 10,000/µL,  G-CSF was discontinued on 
the 6th day of IST.  Transfusion was no longer necessary 
at 42 days after LDLT.  Bone marrow aspirates taken 72 
and 186 days after the LDLT showed hematopoietic 
recovery (Table 1).
The patient continued receiving oral once-daily tac-
rolimus for prophylaxis against allograft rejection after 
the LDLT with a trough level at 4-6 ng/mL.  The eryth-
ropoiesis and leukopoiesis had been stable for 10 years 
with hemoglobin levels at 12-16 g/dL and WBC counts 
4,000-10,000/μL.  However,  the patient had mild 
thrombocytopenia,  with platelet counts 100,000-
200,000/μL.  He had been well without transfusion 
therapy during that time.  The CD4/CD8 ratio remained 
within the reference range from 6 years post-LDLT 
onwards (Table 2).  The results of liver function tests had 
also been within the reference range.  However,  a bone 
marrow examination performed 10 years after the 
LDLT revealed slightly hypoplastic marrow,  with NCC 
87,000/μL (Table 1).  Bone marrow cells showed no 
remarkable dysplastic change,  and their karyotype was 
found to be 46 XY,  using the G-banding method.
Discussion
Our patient developed severe AA following an LDLT 
for fulminant idiopathic hepatic failure.  Immuno-
suppressive therapy with horse ATG and methyl-pred-
nisolone successfully improved his bone marrow failure,  
and his peripheral blood counts were maintained with-
out transfusion therapy for a decade,  although mild 
thrombocytopenia persisted.  Unexpectedly,  a bone 
marrow examination performed 10 years after the onset 
of HAAA revealed a reduction in the patient’s NCC 
count without dysplastic change,  which suggests that 
his impaired bone marrow function was sustained even 
after the successful IST and maintenance tacrolimus 
administration.
Immunosuppressive therapy with ATG is known to 
be effective in improving the hematopoiesis of HAAA 
patients without HLA-matched donors [1].  A prospec-
tive study conducted by the Japan Childhood Aplastic 
Anemia Study Group enrolled 318 children newly diag-
nosed with AA.  Of the 318 patients,  AA was associated 
with hepatitis in 44 patients (14%) [6].  The response 
ratio 12 months after IST reached 75%,  which was 
comparable with the response ratio of IST for idio-
pathic AA (60-80%).  Moreover,  the recurrence of 
HAAA has not been reported among patients who 
responded to IST.
Immunosuppressive therapy is also known to be 
beneficial for HAAA patients receiving LDLT [7 , 8].  
Following an LDLT,  a long-term administration of 
immunosuppressive agents such as cyclosporine or tac-
rolimus is often necessary to prevent graft rejection.  
Maintenance immunosuppressive therapy after LDLT 
has been reported to recover hematopoiesis in patients 
with HAAA,  suggesting that it is effective in suppress-
ing abnormal immune activation [9].
Two cases of recurrent HAAA that was identified 
> 10 years after the first episode have been reported 
[4 , 5].  One case was a Caucasian male who first devel-
oped HAAA at 7 years of age.  The etiology of hepatitis 
was not identified.  Immunosuppressive therapy with 
ATG,  cyclosporine A (CsA) and prednisolone was per-
formed,  and his hematopoiesis recovered.  The patient 
remained well until 20 years of age,  when the second 
episode of HAAA developed.  An investigation of the 
etiology of hepatitis failed again.  A lymphocyte subset 
panel revealed that his CD4/CD8 ratio had fallen to 
0.05.  Immunosuppressive therapy was performed with 
ATG and CsA.  His hematopoiesis recovered 4.5  
months after the initiation of the IST [4].
The other case was a Japanese male who first devel-
oped HAAA at 13 years of age.  Pancytopenia developed 
following idiopathic liver failure,  and he was diagnosed 
as having HAAA.  Immunosuppressive therapy with 
dexamethasone and CsA was performed.  His hemato-
poiesis recovered within 5 months,  and the CsA was 
tapered off over 1 year.  Ten years later,  fulminant hep-
atitis developed,  but once more,  its etiology was not 
identified.  His CD4/CD8 ratio decreased to 0.156.  
Pancytopenia developed,  and he was diagnosed as hav-
ing recurrent HAAA.  Immunosuppressive therapy with 
ATG,  methyl-prednisolone,  and CsA was performed.  
The patient’s hematopoiesis recovered in 6 months,  and 
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Table 2　 Peripheral blood lymphocyte subpopulations over time 
since liver transplant
Time since liver transplant
2 months 6 years 8 years 11 years
CD3+CD4+  (29-65%) 12% 46% 37% 32%
CD3+CD8+  (13-40%) 40% 34% 31% 31%
CD4+/CD8+  (0.6-2.9) 0.3 1.4 1.2 1
Reference ranges are shown in brackets.
his CD4/CD8 ratio increased to 0.42 [5].
These two recurrent HAAA cases raise the specula-
tion that latent,  abnormal immunologic responses 
might have persisted more than a decade after the first 
HAAA episode was successfully treated,  and were 
re-activated by an unknown source and caused the 
patients’ second episodes.
Immune-mediated mechanisms are hypothesized to 
play a pivotal role in the pathophysiology of HAAA.  
Flow cytometry investigations of peripheral blood lym-
phocytes of HAAA patients before they underwent IST 
revealed elevated percentages of CD8 T cells and HLA-
DR-positive CD8 cells,  suggesting the activation of 
cytotoxic T cells [10].  In our patient’s case,  the lym-
phocyte subpopulation analysis also showed an elevated 
percentage of CD8 cells during the active phase of 
HAAA.  However,  it declined to within the reference 
range after the administration of IST (Table 2).
Analyses of the T-cell repertoire in the liver and 
peripheral blood lymphocytes in HAAA patients 
revealed highly skewed Vβ patterns,  as seen in viral or 
autoimmune hepatitis [3].  Such a skewed spectratype 
pattern of HAAA patients’ T cells can be reversed back 
to a normal pattern by intensive IST.  These results sug-
gest that an antigen,  possibly from an unknown virus,  
induces an abnormal autoimmune reaction toward both 
hepatocytes and hematopoietic stem cells,  leading to 
severe acquired AA following hepatitis.
Our patient presented with hypoplastic bone mar-
row,  even after 10 years of successful immunosuppres-
sive therapy for his HAAA.  This indicates that cytotoxic 
T cells which attacked bone marrow cells during the 
HAAA were not completely removed by the IST,  and 
the abnormal immune reaction continued against some 
antigen in the bone marrow cells.  The long-term 
administration of tacrolimus for the prophylaxis of liver 
allograft rejection in our patient’s case may have been 
effective in preventing the relapse of HAAA.
In conclusion,  we have reported a case of HAAA 
with persistent impaired hematopoiesis 10 years after 
successful treatment with immunosuppressive therapy.  
A long-term administration of tacrolimus for prophy-
laxis against liver allograft rejection might be beneficial 
for suppressing the re-activation of cytotoxic T cells,  
which could cause a second episode of HAAA.
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